glp-1 heart attack receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential Cardiovascular Effects of Glucagon-Like Peptide-1

Rosenstock J, Marquard J, Laffel LM et al (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials

They found that treating the mice with GLP-1 agonists normalized the fibrosis-related genes, reprogramming the macrophages that caused the scar tissue buildup

Nausea and vomiting (common when starting the medication but usually temporary) Diarrhea or constipation Mild fatigue or dizziness Loss of muscle mass if weight loss is too rapid A study published in JAMA found that GLP-1s significantly reduce body weight and A1C levels (a marker of blood sugar control) in older adults

Dietary Fiber, Atherosclerosis, and Cardiovascular Disease

A cross-sectional study of GLP-1 users found significant shortfalls in calcium, iron, magnesium, potassium, vitamins A, C, D, and E, plus choline

In clinical trials, patients on Tirzepatide lost up to 21% of body weight, compared to around 15% on Semaglutide, making it an attractive option for patients seeking more aggressive weight loss